Caffeine for Motor Manifestations of Parkinson's Disease
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Caffeine, Parkinson's Disease, Parkinson Disease, Parkinsonian Disorders, Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases, Caffeine citrate, Molecular Mechanisms of Pharmacological Action, Pharmacologic Actions, Central Nervous System Stimulants, Physiological Effects of Drugs, Central Nervous System Agents, Therapeutic Uses
Eligibility Criteria
Inclusion Criteria:
1. Subject has been diagnosed with idiopathic Parkinson's disease (stage I - IV Hoehn and Yahr)
Exclusion Criteria:
- Estimated daily caffeine intake of more than 200 mg per day.
- Subject has dementia (MMSE < 26/30) and ADL impairment secondary to cognitive loss, inability to understand consent process.
- Changes to antiparkinsonian medications in last 4 weeks or changes will be required during the period of the study protocol.
Contraindication to caffeine use:
- Uncontrolled hypertension (systolic bp >170 or diastolic bp >110 on two consecutive readings)
- Use of lithium or clozapine
- Pre-menopausal women who are not using effective methods of birth control
- Current use of prescribed alerting agents such as modafinil and methylphenidate
- Active peptic ulcer disease
- Supraventricular cardiac arrhythmia
- Previous adverse reaction to caffeine which either required admission to hospital,or after which the patient was directly advised by a physician to not use caffeine.
Sites / Locations
- Montreal General Hospital
Arms of the Study
Arm 1
Experimental
Caffeine
Each patient will take pills twice per day containing 100-200 mg of caffeine (as synthetic caffeine alkaloid). Patients will be instructed to take whatever caffeine-containing beverages they are accustomed to taking, without changing their habitual schedule (note that all will be taking <200 mg per day). Caffeine intake will be assessed at each visit. Patients will continue their usual PD medications, without change in dose or timing for the entire duration of the study. Medication will be provided in pre-packaged dosettes.